{"nctId":"NCT01032993","briefTitle":"Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms","startDateStruct":{"date":"2009-12"},"conditions":["Pain","Weakness","Cramps","Myalgia or Myositis Nos","HMG COA Reductase Inhibitor Adverse Reaction"],"count":68,"armGroups":[{"label":"Coenzyme Q10","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Coenzyme Q10"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Coenzyme Q10","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a history of muscle symptoms (such as aches, pains, cramps and/or weakness) while taking a statin drug that persisted for at least 2 weeks on a statin\n\nExclusion Criteria:\n\n* Plasma creatine kinase levels \\> 3 times the upper normal limit\n* Liver enzymes, alanine transferase (ALT) or aspartate transferase (AST) \\> 2 times the upper normal limit\n* Pregnancy or breastfeeding (a contraindication for statin use)\n* Severe renal impairment, defined as glomerular filtration rate (GFR) \\< 30 ml/min/1.73 m2\n* Bleeding disorder, current use of warfarin, an international normalized ratio (INR) greater than 1.5, or a platelet count less than 100,000 mm3\n* Contraindication to strength testing, including myocardial infarction, unstable angina, or revascularization procedure within the past six weeks, a history of brain aneurysm or stroke\n* Chest or abdominal surgery within the past six weeks\n* Severe persistent pain related to other causes\n* Unable to complete self-administered questionnaires, or unable to read or converse in English","healthyVolunteers":true,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use","description":"Clinically significant pain reduction was defined, a priori, as a reduction \\> 1.5 points on the Brief Pain Inventory-Severity Scale (BPI-SS), range: 0 to 10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Continuation of Statin","description":"Adherence of statin use was defined a priori as participant using Simvastatin 20 mg /day at the end of 4 weeks and having used \\>85% of statin doses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Improvement in Disability Related to Muscle Pain","description":"Disability improvement was based on patient report of improvement they felt was meaningful to them","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Effects","description":"serious adverse effects and possible side effects were tracked through all phases of the study by participant interview and checklist at each visit, up to 4 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Nausea/dyspepsia","Fatigue"]}}}